GlassScriptPhysician profile
Ana A Cardenas
NPI 1841292026
$10,623.85
in general payments reported to CMS, 2019-2025
35 companies · $588 in 2025
The $588 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,557 · 2020: $1,172 · 2021: $700 · 2022: $508 · 2023: $329 · 2024: $768 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,676 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,676.19 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $3,991.11 | 2019-2022 | |
| Abbvie INC. | $1,890.64 | 2019-2025 | Rinvoq |
| Medtronic Vascular, INC. | $1,123.35 | 2019 | |
| Amgen INC. | $592.38 | 2020-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $336.12 | 2019-2024 | Tremfya |
| Ucb, INC. | $282.42 | 2019-2025 | Bimzelx |
| Genzyme Corporation | $260.70 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $220.81 | 2019-2023 | Dupixent |
| Pfizer INC. | $175.21 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $164.45 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $150.44 | 2019-2025 | |
| Leo Pharma INC. | $148.70 | 2019-2024 | Adbry |
| Celgene Corporation | $147.98 | 2019 | |
| Lilly USA, LLC | $147.64 | 2019-2022 | |
| Journey Medical Corporation | $142.98 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $129.21 | 2019-2020 | |
| Incyte Corporation | $94.76 | 2024-2025 | Opzelura |
| Vyne Pharmaceuticals INC. | $84.30 | 2020 | |
| Mayne Pharma Commercial LLC | $74.27 | 2019 | |
| Dusa Pharmaceuticals, INC. | $72.25 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $66.21 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $50.60 | 2024-2025 | Sotyktu |
| Almirall LLC | $37.62 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $29.64 | 2019 | |
| Merz North America, INC. | $25.78 | 2022 | |
| Organogenesis INC. | $24.06 | 2024 | Affinity |
| Medtronic, INC. | $23.51 | 2025 | Corevalve Evolut R |
| Boston Scientific Corporation | $21.72 | 2024 | |
| Abbott Laboratories | $21.54 | 2025 | Ensite |
| Biofrontera INC. | $21.08 | 2019 | |
| Dermira, INC. | $20.78 | 2020 | |
| Shockwave Medical, INC | $17.57 | 2021 | |
| Botanix Sb INC | $14.43 | 2025 | Sofdra |
| Merck Sharp & Dohme LLC | $13.66 | 2019 | |
| Organon LLC | $5.93 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Cardenas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.